Supernus (SUPN) Insider Exercise and 10b5-1 Sales Total $11.19M
Rhea-AI Filing Summary
Form 144 filing for Supernus Pharmaceuticals, Inc. (SUPN) reports a proposed sale of 29,513 shares of common stock through Morgan Stanley Smith Barney on 09/23/2025 to be executed on the NASDAQ. The shares were acquired and paid for on 09/23/2025 by exercise of stock options, with payment in cash. The filing also lists multiple Rule 10b5-1 sales by Jack A. Khattar over August–September 2025, showing several transactions and gross proceeds. The notice includes the seller's representation regarding absence of undisclosed material information.
Positive
- None.
Negative
- Multiple recent 10b5-1 sales totaled approximately $11,194,631.04 in gross proceeds across transactions dated 08/06/2025–09/22/2025, as listed in the filing
Insights
TL;DR Insider exercised options and proposes an immediate sale of 29,513 shares; several prior 10b5-1 sales occurred in Aug–Sep 2025.
The filing shows a routine Form 144 notice: shares were acquired by exercise of stock options and payment was made in cash the same day, indicating these are not open-market transfers from inherited or gifted shares. The broker listed is Morgan Stanley Smith Barney and the transaction is slated for NASDAQ. The document documents numerous recent 10b5-1 sales by Jack A. Khattar, reflecting ongoing systematic disposition activity rather than a single ad-hoc sale.
TL;DR This is a compliance-focused disclosure showing planned insider sales and prior 10b5-1 transactions, with standard attestations.
The notice includes the required attestation that the seller is not aware of undisclosed material adverse information and references a broker and planned sale date. The presence of multiple 10b5-1 entries demonstrates use of pre-arranged trading plans, which is consistent with governance best practices for scheduled insider sales. No new corporate actions or governance changes are disclosed in this filing.